Annual Retained Earnings
-$354.37 M
-$44.80 M-14.47%
31 December 2023
Summary:
Galectin Therapeutics annual retained earnings is currently -$354.37 million, with the most recent change of -$44.80 million (-14.47%) on 31 December 2023. During the last 3 years, it has fallen by -$114.38 million (-47.66%). GALT annual retained earnings is now -8429.01% below its all-time high of -$4.15 million, reached on 31 December 2001.GALT Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Retained Earnings
-$389.54 M
-$11.24 M-2.97%
30 September 2024
Summary:
Galectin Therapeutics quarterly retained earnings is currently -$389.54 million, with the most recent change of -$11.24 million (-2.97%) on 30 September 2024. Over the past year, it has dropped by -$45.23 million (-13.14%). GALT quarterly retained earnings is now -41314.20% below its all-time high of -$940.60 thousand, reached on 30 June 2001.GALT Quarterly Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GALT Retained Earnings Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -14.5% | -13.1% |
| 3 y3 years | -47.7% | -47.9% |
| 5 y5 years | -80.6% | -84.5% |
GALT Retained Earnings High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -47.7% | at low | -47.9% | at low |
| 5 y | 5 years | -80.6% | at low | -84.5% | at low |
| alltime | all time | -8429.0% | at low | <-9999.0% | at low |
Galectin Therapeutics Retained Earnings History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | -$389.54 M(+3.0%) |
| June 2024 | - | -$378.30 M(+3.4%) |
| Mar 2024 | - | -$365.87 M(+3.2%) |
| Dec 2023 | -$354.37 M(+14.5%) | -$354.37 M(+2.9%) |
| Sept 2023 | - | -$344.31 M(+4.3%) |
| June 2023 | - | -$330.27 M(+2.9%) |
| Mar 2023 | - | -$321.09 M(+3.7%) |
| Dec 2022 | -$309.57 M(+14.4%) | -$309.57 M(+3.6%) |
| Sept 2022 | - | -$298.87 M(+3.0%) |
| June 2022 | - | -$290.29 M(+3.4%) |
| Mar 2022 | - | -$280.61 M(+3.7%) |
| Dec 2021 | -$270.69 M(+12.8%) | -$270.69 M(+2.8%) |
| Sept 2021 | - | -$263.41 M(+3.4%) |
| June 2021 | - | -$254.85 M(+3.5%) |
| Mar 2021 | - | -$246.34 M(+2.6%) |
| Dec 2020 | -$240.00 M(+10.9%) | -$240.00 M(+3.4%) |
| Sept 2020 | - | -$232.08 M(+2.6%) |
| June 2020 | - | -$226.13 M(+2.8%) |
| Mar 2020 | - | -$219.94 M(+1.6%) |
| Dec 2019 | -$216.39 M(+10.3%) | -$216.39 M(+2.5%) |
| Sept 2019 | - | -$211.19 M(+1.4%) |
| June 2019 | - | -$208.37 M(+1.5%) |
| Mar 2019 | - | -$205.31 M(+4.6%) |
| Dec 2018 | -$196.22 M(+8.3%) | -$196.22 M(+1.7%) |
| Sept 2018 | - | -$192.87 M(+1.6%) |
| June 2018 | - | -$189.82 M(+2.2%) |
| Mar 2018 | - | -$185.71 M(+2.5%) |
| Dec 2017 | -$181.17 M(+10.7%) | -$181.17 M(+1.6%) |
| Sept 2017 | - | -$178.38 M(+2.7%) |
| June 2017 | - | -$173.72 M(+2.8%) |
| Mar 2017 | - | -$168.91 M(+3.2%) |
| Dec 2016 | -$163.70 M(+16.9%) | -$163.70 M(+3.3%) |
| Sept 2016 | - | -$158.52 M(+3.7%) |
| June 2016 | - | -$152.89 M(+4.0%) |
| Mar 2016 | - | -$147.06 M(+5.0%) |
| Dec 2015 | -$140.05 M(+17.8%) | -$140.05 M(+3.7%) |
| Sept 2015 | - | -$135.08 M(+4.8%) |
| June 2015 | - | -$128.93 M(+4.0%) |
| Mar 2015 | - | -$124.00 M(+4.3%) |
| Dec 2014 | -$118.92 M(+16.6%) | -$118.92 M(+3.5%) |
| Sept 2014 | - | -$114.89 M(+3.4%) |
| June 2014 | - | -$111.10 M(+3.5%) |
| Mar 2014 | - | -$107.37 M(+5.3%) |
| Dec 2013 | -$101.97 M(+27.4%) | -$101.97 M(+3.2%) |
| Sept 2013 | - | -$98.85 M(+3.9%) |
| June 2013 | - | -$95.13 M(+13.9%) |
| Mar 2013 | - | -$83.49 M(+4.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2012 | -$80.02 M(+15.7%) | -$80.02 M(+3.5%) |
| Sept 2012 | - | -$77.31 M(+4.0%) |
| June 2012 | - | -$74.33 M(+4.2%) |
| Mar 2012 | - | -$71.34 M(+3.2%) |
| Dec 2011 | -$69.14 M(+22.5%) | -$69.14 M(+5.7%) |
| Sept 2011 | - | -$65.42 M(+3.7%) |
| June 2011 | - | -$63.08 M(+6.7%) |
| Mar 2011 | - | -$59.15 M(+4.8%) |
| Dec 2010 | -$56.42 M(+18.3%) | -$56.42 M(+2.8%) |
| Sept 2010 | - | -$54.91 M(+3.6%) |
| June 2010 | - | -$53.01 M(+4.9%) |
| Mar 2010 | - | -$50.53 M(+5.9%) |
| Dec 2009 | -$47.72 M(+23.8%) | -$47.72 M(+2.8%) |
| Sept 2009 | - | -$46.41 M(+4.3%) |
| June 2009 | - | -$44.49 M(+8.1%) |
| Mar 2009 | - | -$41.16 M(+6.8%) |
| Dec 2008 | -$38.55 M(+9.6%) | -$38.55 M(+2.3%) |
| Sept 2008 | - | -$37.68 M(-0.1%) |
| June 2008 | - | -$37.71 M(+1.5%) |
| Mar 2008 | - | -$37.15 M(+5.6%) |
| Dec 2007 | -$35.16 M(+36.7%) | -$35.16 M(+3.9%) |
| Sept 2007 | - | -$33.85 M(+8.3%) |
| June 2007 | - | -$31.27 M(-0.1%) |
| Mar 2007 | - | -$31.30 M(+21.7%) |
| Dec 2006 | -$25.73 M(-2.7%) | -$25.73 M(-24.8%) |
| Sept 2006 | - | -$34.20 M(-2.1%) |
| June 2006 | - | -$34.92 M(+3.5%) |
| Mar 2006 | - | -$33.74 M(+27.7%) |
| Dec 2005 | -$26.43 M(+32.9%) | -$26.43 M(+7.1%) |
| Sept 2005 | - | -$24.68 M(+7.3%) |
| June 2005 | - | -$23.00 M(+8.0%) |
| Mar 2005 | - | -$21.30 M(+7.1%) |
| Dec 2004 | -$19.89 M(+56.5%) | -$19.89 M(+12.2%) |
| Sept 2004 | - | -$17.73 M(+11.0%) |
| June 2004 | - | -$15.96 M(+9.6%) |
| Mar 2004 | - | -$14.56 M(+14.6%) |
| Dec 2003 | -$12.71 M(+62.2%) | -$12.71 M(+14.1%) |
| Sept 2003 | - | -$11.14 M(+14.2%) |
| June 2003 | - | -$9.75 M(+11.1%) |
| Mar 2003 | - | -$8.78 M(+12.1%) |
| Dec 2002 | -$7.83 M(+88.5%) | -$7.83 M(+16.6%) |
| Sept 2002 | - | -$6.72 M(+11.0%) |
| June 2002 | - | -$6.05 M(+18.4%) |
| Mar 2002 | - | -$5.11 M(+23.0%) |
| Dec 2001 | -$4.15 M | -$4.15 M(+155.4%) |
| Sept 2001 | - | -$1.63 M(+73.0%) |
| June 2001 | - | -$940.60 K |
FAQ
- What is Galectin Therapeutics annual retained earnings?
- What is the all time high annual retained earnings for Galectin Therapeutics?
- What is Galectin Therapeutics annual retained earnings year-on-year change?
- What is Galectin Therapeutics quarterly retained earnings?
- What is the all time high quarterly retained earnings for Galectin Therapeutics?
- What is Galectin Therapeutics quarterly retained earnings year-on-year change?
What is Galectin Therapeutics annual retained earnings?
The current annual retained earnings of GALT is -$354.37 M
What is the all time high annual retained earnings for Galectin Therapeutics?
Galectin Therapeutics all-time high annual retained earnings is -$4.15 M
What is Galectin Therapeutics annual retained earnings year-on-year change?
Over the past year, GALT annual retained earnings has changed by -$44.80 M (-14.47%)
What is Galectin Therapeutics quarterly retained earnings?
The current quarterly retained earnings of GALT is -$389.54 M
What is the all time high quarterly retained earnings for Galectin Therapeutics?
Galectin Therapeutics all-time high quarterly retained earnings is -$940.60 K
What is Galectin Therapeutics quarterly retained earnings year-on-year change?
Over the past year, GALT quarterly retained earnings has changed by -$45.23 M (-13.14%)